

Canopy Biosciences Announces Distribution Agreement with Cosmo Bio

23 June 2017 | News

The genetic engineering market continues to grow at a rapid pace in Japan and Cosmo Bio anticipates that the TUNR technology will become a key factor in gene editing.



Canopy Biosciences, an emerging provider of gene editing and personalized medicine technologies, announced a distributor agreement with Cosmo Bio Co., Ltd. for its TUNR Flexible Gene Editing technology in Japan. Cosmo Bio is one of Japan's largest and most established reagents and services suppliers in the life science industry, and Canopy Biosciences will work with Cosmo Bio to gain direct access to customers and support projects throughout the Japanese academic and biopharmaceutical industry.

The genetic engineering market continues to grow at a rapid pace in Japan and Cosmo Bio anticipates that the TUNR technology will become a key factor in gene editing.

Canopy Biosciences was formed in 2016, collaborating with leading research institutions to turn their discoveries into tangible products and make them available to the entire research community. Canopy Biosciences was formed with investment from BioGenerator, an evergreen investor in the St. Louis region.

Cosmo Bio was formed in 1983, an organization established to sell and distribute biological reagents and services for research purposes, headquartered in Tokyo, with a network of over 200 contracted dealers throughout Japan.